Half-year report · Q2
2370.TEDINET S100VQZZ
Period2024-10-01 → 2025-03-31
Filed2025-05-14
StandardJapan GAAP
ConsolidatedNo
Data checks12 of 12 passed
Key figures · 45
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥405m | 2024-10-01 → 2025-03-31 | Standalone | Net sales |
| Revenue | ¥769m | 2023-10-01 → 2024-09-30 | Standalone | Net sales (5-year summary) |
| Revenue | ¥400m | 2023-10-01 → 2024-03-31 | Standalone | Net sales |
| Operating income | −¥756m | 2024-10-01 → 2025-03-31 | Standalone | Operating income |
| Operating income | −¥659m | 2023-10-01 → 2024-03-31 | Standalone | Operating income |
| Ordinary income | −¥711m | 2024-10-01 → 2025-03-31 | Standalone | Ordinary income |
| Ordinary income | −¥1.3bn | 2023-10-01 → 2024-09-30 | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | −¥633m | 2023-10-01 → 2024-03-31 | Standalone | Ordinary income |
| Profit before tax | −¥704m | 2024-10-01 → 2025-03-31 | Standalone | Income before income taxes |
| Profit before tax | −¥633m | 2023-10-01 → 2024-03-31 | Standalone | Income before income taxes |
| Net income | −¥706m | 2024-10-01 → 2025-03-31 | Standalone | Profit loss |
| Net income | −¥1.3bn | 2023-10-01 → 2024-09-30 | Standalone | Net income loss (5-year summary) |
| Net income | −¥634m | 2023-10-01 → 2024-03-31 | Standalone | Profit loss |
| Total assets | ¥5.4bn | at 2025-03-31 | Standalone | Assets |
| Total assets | ¥5.7bn | at 2024-09-30 | Standalone | Assets |
| Total assets | ¥6.1bn | at 2024-03-31 | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥1.0bn | at 2025-03-31 | Standalone | Liabilities |
| Total liabilities | ¥509m | at 2024-09-30 | Standalone | Liabilities |
| Net assets / equity | ¥4.4bn | at 2025-03-31 | Standalone | Net assets |
| Net assets / equity | ¥5.2bn | at 2024-09-30 | Standalone | Net assets |
| Net assets / equity | ¥5.6bn | at 2024-03-31 | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥3.4bn | at 2025-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥4.7bn | at 2024-09-30 | Standalone | Cash and deposits |
| Cash & equivalents | ¥2.4bn | at 2025-03-31 | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥4.7bn | at 2024-09-30 | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥4.9bn | at 2024-03-31 | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥4.4bn | at 2023-09-30d | Standalone | Cash and cash equivalents |
| Operating cash flow | −¥754m | 2024-10-01 → 2025-03-31 | Standalone | Net cash provided by used in operating activities |
| Operating cash flow | −¥1.3bn | 2023-10-01 → 2024-09-30 | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥573m | 2023-10-01 → 2024-03-31 | Standalone | Net cash provided by used in operating activities |
| Investing cash flow | −¥1.5bn | 2024-10-01 → 2025-03-31 | Standalone | Net cash provided by used in investment activities |
| Investing cash flow | ¥65m | 2023-10-01 → 2024-09-30 | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥17m | 2023-10-01 → 2024-03-31 | Standalone | Net cash provided by used in investment activities |
| Financing cash flow | −¥2m | 2024-10-01 → 2025-03-31 | Standalone | Net cash provided by used in financing activities |
| Financing cash flow | ¥1.5bn | 2023-10-01 → 2024-09-30 | Standalone | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥1.1bn | 2023-10-01 → 2024-03-31 | Standalone | Net cash provided by used in financing activities |
| EPS (basic) | ¥-2.67 | 2024-10-01 → 2025-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-5.04 | 2023-10-01 → 2024-09-30 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-2.55 | 2023-10-01 → 2024-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| Equity ratio | 81.5% | at 2025-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 91.1% | at 2024-09-30 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 91.2% | at 2024-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Shares issued | 264,729,198 | at 2025-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 264,515,306 | at 2024-09-30 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 256,190,306 | at 2024-03-31 | Standalone | Total number of issued shares (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 20
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | segment profit | 2024-10-01 → 2025-03-31 | −¥307m |
| jpcrp040300-q2r_E05351-000Cellular And Tissue Based Product Businessreportable segment | revenue | 2024-10-01 → 2025-03-31 | ¥186,000 |
| jpcrp040300-q2r_E05351-000Cellular And Tissue Based Product Businessreportable segment | revenue external | 2024-10-01 → 2025-03-31 | ¥186,000 |
| jpcrp040300-q2r_E05351-000Cellular And Tissue Based Product Businessreportable segment | segment profit | 2024-10-01 → 2025-03-31 | −¥217m |
| jpcrp040300-q2r_E05351-000Contract Cell Manufacturing Businessreportable segment | revenue | 2024-10-01 → 2025-03-31 | ¥405m |
| jpcrp040300-q2r_E05351-000Contract Cell Manufacturing Businessreportable segment | revenue external | 2024-10-01 → 2025-03-31 | ¥405m |
| jpcrp040300-q2r_E05351-000Contract Cell Manufacturing Businessreportable segment | segment profit | 2024-10-01 → 2025-03-31 | −¥232m |
| —segment total | revenue | 2024-10-01 → 2025-03-31 | ¥405m |
| —segment total | revenue external | 2024-10-01 → 2025-03-31 | ¥405m |
| —segment total | segment profit | 2024-10-01 → 2025-03-31 | −¥448m |
| Reconciling Itemsreconciling | segment profit | 2023-10-01 → 2024-03-31 | −¥286m |
| jpcrp040300-q2r_E05351-000Cellular And Tissue Based Product Businessreportable segment | revenue | 2023-10-01 → 2024-03-31 | ¥166,000 |
| jpcrp040300-q2r_E05351-000Cellular And Tissue Based Product Businessreportable segment | revenue external | 2023-10-01 → 2024-03-31 | ¥166,000 |
| jpcrp040300-q2r_E05351-000Cellular And Tissue Based Product Businessreportable segment | segment profit | 2023-10-01 → 2024-03-31 | −¥219m |
| jpcrp040300-q2r_E05351-000Contract Cell Manufacturing Businessreportable segment | revenue | 2023-10-01 → 2024-03-31 | ¥400m |
| jpcrp040300-q2r_E05351-000Contract Cell Manufacturing Businessreportable segment | revenue external | 2023-10-01 → 2024-03-31 | ¥400m |
| jpcrp040300-q2r_E05351-000Contract Cell Manufacturing Businessreportable segment | segment profit | 2023-10-01 → 2024-03-31 | −¥154m |
| —segment total | revenue | 2023-10-01 → 2024-03-31 | ¥400m |
| —segment total | revenue external | 2023-10-01 → 2024-03-31 | ¥400m |
| —segment total | segment profit | 2023-10-01 → 2024-03-31 | −¥373m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 457
| Item | Context | Value | Unit |
|---|---|---|---|
| Cash and cash equivalents | Prior1QuarterInstant_NonConsolidatedMember | 4901287000 | JPY |
| Cash and cash equivalents | CurrentQuarterInstant_NonConsolidatedMember | 2351191000 | JPY |
| Provision for bonuses sga | Prior1YTDDuration_NonConsolidatedMember | 26737000 | JPY |
| Provision for bonuses sga | CurrentYTDDuration_NonConsolidatedMember | 29336000 | JPY |
| Provision for share based payments sga | Prior1YTDDuration_NonConsolidatedMember | 5385000 | JPY |
| Provision for share based payments sga | CurrentYTDDuration_NonConsolidatedMember | 6117000 | JPY |
| Research and development expenses sga | Prior1YTDDuration_NonConsolidatedMember | 223765000 | JPY |
| Research and development expenses sga | CurrentYTDDuration_NonConsolidatedMember | 234484000 | JPY |
| Provision of allowance for doubtful accounts sga | Prior1YTDDuration_NonConsolidatedMember | -828000 | JPY |
| Provision of allowance for doubtful accounts sga | CurrentYTDDuration_NonConsolidatedMember | － | JPY |
| Revenues from external customers | Prior1YTDDuration_NonConsolidatedMember_jpcrp040300-q2r_E05351-000ContractCellManufacturingBusinessReportableSegmentsMember | 399528000 | JPY |
| Revenues from external customers | Prior1YTDDuration_NonConsolidatedMember_jpcrp040300-q2r_E05351-000CellularAndTissueBasedProductBusinessReportableSegmentsMember | 166000 | JPY |
| Revenues from external customers | Prior1YTDDuration_NonConsolidatedMember_ReportableSegmentsMember | 399694000 | JPY |
| Revenues from external customers | Prior1YTDDuration_NonConsolidatedMember_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | Prior1YTDDuration_NonConsolidatedMember | 399694000 | JPY |
| Transactions with other segments | Prior1YTDDuration_NonConsolidatedMember_jpcrp040300-q2r_E05351-000ContractCellManufacturingBusinessReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_NonConsolidatedMember_jpcrp040300-q2r_E05351-000CellularAndTissueBasedProductBusinessReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_NonConsolidatedMember_ReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_NonConsolidatedMember_ReconcilingItemsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_NonConsolidatedMember | － | JPY |
| Net sales | Prior1YTDDuration_NonConsolidatedMember_jpcrp040300-q2r_E05351-000ContractCellManufacturingBusinessReportableSegmentsMember | 399528000 | JPY |
| Net sales | Prior1YTDDuration_NonConsolidatedMember_jpcrp040300-q2r_E05351-000CellularAndTissueBasedProductBusinessReportableSegmentsMember | 166000 | JPY |
| Net sales | Prior1YTDDuration_NonConsolidatedMember_ReportableSegmentsMember | 399694000 | JPY |
| Net sales | Prior1YTDDuration_NonConsolidatedMember_ReconcilingItemsMember | － | JPY |
| Net sales | Prior1YTDDuration_NonConsolidatedMember | 399694000 | JPY |
| Operating income | Prior1YTDDuration_NonConsolidatedMember_jpcrp040300-q2r_E05351-000ContractCellManufacturingBusinessReportableSegmentsMember | -154038000 | JPY |
| Operating income | Prior1YTDDuration_NonConsolidatedMember_jpcrp040300-q2r_E05351-000CellularAndTissueBasedProductBusinessReportableSegmentsMember | -219198000 | JPY |
| Operating income | Prior1YTDDuration_NonConsolidatedMember_ReportableSegmentsMember | -373237000 | JPY |
| Operating income | Prior1YTDDuration_NonConsolidatedMember_ReconcilingItemsMember | -285519000 | JPY |
| Operating income | Prior1YTDDuration_NonConsolidatedMember | -658757000 | JPY |
| Revenues from external customers | CurrentYTDDuration_NonConsolidatedMember_jpcrp040300-q2r_E05351-000ContractCellManufacturingBusinessReportableSegmentsMember | 404600000 | JPY |
| Revenues from external customers | CurrentYTDDuration_NonConsolidatedMember_jpcrp040300-q2r_E05351-000CellularAndTissueBasedProductBusinessReportableSegmentsMember | 186000 | JPY |
| Revenues from external customers | CurrentYTDDuration_NonConsolidatedMember_ReportableSegmentsMember | 404787000 | JPY |
| Revenues from external customers | CurrentYTDDuration_NonConsolidatedMember_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | CurrentYTDDuration_NonConsolidatedMember | 404787000 | JPY |
| Transactions with other segments | CurrentYTDDuration_NonConsolidatedMember_jpcrp040300-q2r_E05351-000ContractCellManufacturingBusinessReportableSegmentsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_NonConsolidatedMember_jpcrp040300-q2r_E05351-000CellularAndTissueBasedProductBusinessReportableSegmentsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_NonConsolidatedMember_ReportableSegmentsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_NonConsolidatedMember_ReconcilingItemsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_NonConsolidatedMember | － | JPY |
| Net sales | CurrentYTDDuration_NonConsolidatedMember_jpcrp040300-q2r_E05351-000ContractCellManufacturingBusinessReportableSegmentsMember | 404600000 | JPY |
| Net sales | CurrentYTDDuration_NonConsolidatedMember_jpcrp040300-q2r_E05351-000CellularAndTissueBasedProductBusinessReportableSegmentsMember | 186000 | JPY |
| Net sales | CurrentYTDDuration_NonConsolidatedMember_ReportableSegmentsMember | 404787000 | JPY |
| Net sales | CurrentYTDDuration_NonConsolidatedMember_ReconcilingItemsMember | － | JPY |
| Net sales | CurrentYTDDuration_NonConsolidatedMember | 404787000 | JPY |
| Operating income | CurrentYTDDuration_NonConsolidatedMember_jpcrp040300-q2r_E05351-000ContractCellManufacturingBusinessReportableSegmentsMember | -231709000 | JPY |
| Operating income | CurrentYTDDuration_NonConsolidatedMember_jpcrp040300-q2r_E05351-000CellularAndTissueBasedProductBusinessReportableSegmentsMember | -216711000 | JPY |
| Operating income | CurrentYTDDuration_NonConsolidatedMember_ReportableSegmentsMember | -448421000 | JPY |
| Operating income | CurrentYTDDuration_NonConsolidatedMember_ReconcilingItemsMember | -307458000 | JPY |
| Operating income | CurrentYTDDuration_NonConsolidatedMember | -755879000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |